Clinical Trial Update: 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the combination of 177Lu-DOTA-TATE with Olaparib in somatostatin receptor-positive tumors has completed. The study includes neur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesothelioma
• Neuroendocrine Tumors
• Thymoma

Drugs mentioned

• 177Lu-DOTA-TATE (Lutetium-177 DOTATATE)
• Olaparib (Olaparib)

Snippet

Sponsor: Vastra Gotaland Region | Conditions: Clinical Trial, Phase I, Neuroendocrine Tumors | Phase 1 | Status: COMPLETED